Enanta PharmaceuticalsvsMerck & Company

ENTA and MRK stock compared: price, dividend, valuation and results, from SEC filings.

ENTA

Enanta Pharmaceuticals, Inc.

$8.45

Value $244M

-2.76%
ENTA's page

MRK

Merck & Company, Inc.

$141.16

Value $349B

-1.75%
MRK's page

Enanta Pharmaceuticals (ENTA) has a market value of $244M and Merck & Company (MRK) $349B. Over the last year, with dividends, ENTA moved -34.1% and MRK +56.2%. Dividend yield: ENTA none, MRK 2.41%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ENTA$244M

    MRK$349B

    MRK is 1,431 times ENTA

  • Revenue, 12 months

    ENTA$65M

    MRK$67.4B

    MRK is 1,032 times ENTA

  • Net income, 12 months

    ENTA-$63M

    MRK$2.5B

  • Operating margin

    ENTA-90.0%

    MRK–

  • ROIC

    ENTA-47.5%

    MRK3.9%

    51.4 points apart

  • P/E

    ENTA–

    MRK142.3

  • Dividend yield

    ENTA0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    ENTA-90.8%

    MRK+98.6%

    189.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ENTA-90.8%

MRK+98.6%

010020020222023202420252026
Returns by period
PeriodENTAWith dividendsMRKWith dividends
1 year since November 17, 2025-34.1%Price -34.1%+56.2%Price +51.7%
3 years since November 17, 2023-7.4%-2.5% a yearPrice -7.4%+51.7%+14.9% a yearPrice +38.4%
5 years since November 17, 2021-90.8%-38.0% a yearPrice -90.8%+98.6%+14.7% a yearPrice +70.5%
10 years since November 18, 2016-71.8%-11.9% a yearPrice -71.8%+223.7%+12.5% a yearPrice +138.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ENTAEnanta PharmaceuticalsMRKMerck & Company

Valuation

ENTAMRK
Valuation
Price$8.45$141.16
Market value$244M$349B
Enterprise value (EV)–$393B
P/E–142.3
P/E, 5-year median–14.8
P/B2.47.8
EV/EBIT–82.6
Free cash flow yield–4.2%

Results and growth

ENTAMRK
Results and growth
Revenue, 12 months$65M$67.4B
Net income, 12 months-$63M$2.5B
Free cash flow, 12 months-$37M$14.7B
Earnings per share, 12 months-$2.42$0.98
Revenue growth, year on year-3.4%1.3%
Revenue growth a year, past-11.8%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

ENTAMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin-90.0%–
Net margin-96.9%3.6%
ROIC-47.5%3.9%
ROE-64.8%5.2%

Balance sheet

ENTAMRK
Balance sheet
Cash$190M$9.7B
Total debt–$53.8B
Net debt / EBITDA–5.7
Interest cover-4.6×2.4×

Dividends and buybacks

ENTAMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–3.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ENTA or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Enanta Pharmaceuticals or Merck & Company?

By market value, Merck & Company ($349B) is about 1,431.0 times Enanta Pharmaceuticals ($244M), at today's prices.

How did ENTA and MRK stock do over the last 10 years?

Since November 18, 2016, ENTA's price moved -71.8% and MRK's +138.6%. With dividends: ENTA -71.8% (-11.9% a year), MRK +223.7% (+12.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, ENTA or MRK?

The dividend yield at today's price is none for Enanta Pharmaceuticals and 2.41% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Enanta Pharmaceuticals or Merck & Company?

Over the last twelve months, the net margin was -96.9% for Enanta Pharmaceuticals and 3.6% for Merck & Company, and the operating margin -90.0% and –. Revenue was $65M and $67.4B.

Which is the better investment, Enanta Pharmaceuticals or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.